Guardant Health, Inc. $GH Stock Position Reduced by Eventide Asset Management LLC

Eventide Asset Management LLC trimmed its holdings in Guardant Health, Inc. (NASDAQ:GH) by 24.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 2,511,091 shares of the company’s stock after selling 810,247 shares during the quarter. Guardant Health makes up 4.0% of Eventide Asset Management LLC’s investment portfolio, making the stock its largest position. Eventide Asset Management LLC’s holdings in Guardant Health were worth $256,455,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Erste Asset Management GmbH grew its position in Guardant Health by 10.4% in the third quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock worth $43,716,000 after acquiring an additional 66,617 shares in the last quarter. Segall Bryant & Hamill LLC grew its position in Guardant Health by 57.8% in the third quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock worth $19,066,000 after acquiring an additional 111,822 shares in the last quarter. World Investment Advisors bought a new stake in Guardant Health in the fourth quarter worth approximately $1,664,000. TD Asset Management Inc grew its position in Guardant Health by 16.1% in the third quarter. TD Asset Management Inc now owns 188,810 shares of the company’s stock worth $11,797,000 after acquiring an additional 26,210 shares in the last quarter. Finally, GSA Capital Partners LLP grew its position in Guardant Health by 155.5% in the third quarter. GSA Capital Partners LLP now owns 21,982 shares of the company’s stock worth $1,373,000 after acquiring an additional 13,378 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, insider John G. Saia sold 20,000 shares of the stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $106.51, for a total value of $2,130,200.00. Following the completion of the transaction, the insider owned 45,950 shares in the company, valued at approximately $4,894,134.50. This represents a 30.33% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 210,000 shares of the stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $109.89, for a total transaction of $23,076,900.00. Following the completion of the transaction, the chief executive officer owned 1,886,504 shares of the company’s stock, valued at approximately $207,307,924.56. This represents a 10.02% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 452,238 shares of company stock worth $51,425,612. Insiders own 5.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on GH. The Goldman Sachs Group began coverage on shares of Guardant Health in a research report on Friday, June 5th. They issued a “buy” rating and a $165.00 target price for the company. Leerink Partners boosted their target price on shares of Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday, February 20th. Canaccord Genuity Group boosted their target price on shares of Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Stifel Nicolaus boosted their target price on shares of Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Finally, Wells Fargo & Company boosted their target price on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $141.95.

Guardant Health Price Performance

Shares of Guardant Health stock opened at $131.62 on Friday. Guardant Health, Inc. has a 52-week low of $40.35 and a 52-week high of $134.28. The firm has a market capitalization of $17.45 billion, a PE ratio of -38.83 and a beta of 1.61. The company’s fifty day moving average price is $103.51 and its two-hundred day moving average price is $102.14.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.